PALO ALTO, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results